

Circulating tumor DNA analysis integrating tumor clonality detects minimal residual disease in resectable non-small-cell lung cancer

Rong Yin¹, Siwei Wang¹, Min Wu², Ming Li¹, Hua Bao², Feng Jiang¹, Jie Wang¹, Xue Wu², Yang Shao^{2,3}, Lin Xu¹

¹Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China; ²Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China; ³School of Public Health, Nanjing Medical University, Nanjing, China.

Background

- Circulating tumor DNA (ctDNA) has been proven as a marker for detecting minimal residual disease (MRD) in mid-to-late stage non-small-cell lung cancers (NSCLCs) that received radio-, chemo-, immuno-, and/or targeted therapies.^{1,2,3}
- The usefulness of ctDNA in monitoring MRD in resectable stage I-III NSCLC patients after curative surgeries has not been validated.
- It also remains not fully understood whether tracking clonal evolution of tissues in ctDNA could further improve the risk stratification.³
- We attempt to evaluate MRD using ctDNA and tumor clonality information in NSCLC patients that received surgeries with curative intent.

Methods

- We profiled tissue mutations of 127 patients with stage I-III NSCLCs in the Lung Cancer Tempo-spatial Heterogeneity (LuCaTH) prospective cohort, and reconstructed individual clonal phylogenetics based on a total of 593 tissue samples.
- We collected plasma samples at baseline, 7 days post surgery, and every 3 months thereafter, and performed deep targeted sequencing (median: 4086X) on a total of 634 plasma samples using a panel covering 425 cancer-associated genes.
- All patients were monitored for at least two time points after surgeries and followed up for a median of 894 days.
- Plasma mutations were matched to tissue profiles, polished with a control pool of healthy individuals, and filtered for clonal mutations and highly confident subclonal mutations.

References

1. Chaudhuri, Aadel A., et al. Cancer discovery 7.12 (2017): 1394-1403.
2. Pécuchet, Nicolas, et al. PLoS medicine 13.12 (2016): e1002199.
3. Abbosh, Christopher, et al. Nature 545.7655 (2017): 446-451.

Disclosure

M.W., H.B., X.W., and Y.S. are employees of Nanjing Geneseeq Technology Inc.

Figure 1. Overview of sample collection and patient demography




Figure 2. Detection of ctDNA at different pathological stages




Figure 2: ctDNA was more frequently detected in patients with more advanced diseases both pre- and post-surgically.

Figure 3. Post-surgical ctDNA detection indicated higher risk of relapse




Figure 3: ctDNA detection at 7 days post surgeries and during longitudinal monitoring indicated higher risk of relapse (HR = 3.90 & 7.59, respectively). Longitudinal ctDNA monitoring achieved 73.5% sensitivity for predicting relapse occurrence while maintaining 81.9% specificity.

Figure 4. Detection of ctDNA during longitudinal monitoring in relapse cases




Figure 5. ctDNA detection led radiological relapse




Figure 5: ctDNA detection during longitudinal monitoring led radiological relapse by a median of 144 days in LUAD cases and 150 days in LUSC cases.

Results

- Both baseline and postsurgical ctDNA were more frequently detected in patients with more advanced diseases.
- The detection of postsurgical ctDNA at 7 days and during longitudinal monitoring indicated higher risk of relapse (HR: 3.90 and 7.95; P = 0.00011 and P < 0.0001, respectively).
- ctDNA detection during longitudinal monitoring had 73.5% sensitivity at 81.9% specificity for predicting relapse occurrence in the investigation period.
- ctDNA detection during longitudinal monitoring led radiological relapse by a median of 145 days.

Conclusions

- ctDNA analysis integrating tumor clonality may provide evidence for minimal residual disease in NSCLC patients who receive curative surgeries.